XFM and HERFD-XAS studies demonstrate bioaccumulation of selenium in mice, indicating differing selenocompound effectiveness.
These results support the hypothesised in vivo reduction of SeN and subsequent bioaccumulation in the blood and various tissues. The present findings highlight marked differences in the bioavailability and utilisation of these purported therapeutic selenocompounds.
No takes yet. Share an insight, caveat, or question.
Baker et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: